Podcast: Emergex CEO Questions mRNA Vaccines Against ‘Wuhan Virus’, Works On Universal Vaccines
Seeks More Partners For New Delivery Modes
Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.
